TP53 and cancer: To evaluate the role of candidate oncoRBPs in immune evasion, we first assessed TP53-mutated C5-like cell models from the Cancer Cell Line Encyclopedia (CCLE), since TP53 mutation is a hallmark of HGSC that distinguishes it from other ovarian cancer histological subtypes.3 Among these, we identified ES-2, OVCAR-8, along with endometrial cancer-derived TOV112D, as top-ranking models, characterized by high proliferative capacity and strong immune suppression (Supplementary Fig. S2a).